Kornitzer Capital Management Inc. KS Trims Stake in Natera, Inc. (NASDAQ:NTRA)

Kornitzer Capital Management Inc. KS decreased its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 8.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 336,329 shares of the medical research company's stock after selling 31,165 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.28% of Natera worth $21,068,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. RiverPark Advisors LLC purchased a new stake in Natera in the fourth quarter worth $27,000. Oliver Lagore Vanvalin Investment Group grew its position in shares of Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company's stock worth $47,000 after buying an additional 389 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new position in shares of Natera during the 3rd quarter worth $44,000. CWM LLC grew its position in shares of Natera by 224.4% during the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company's stock worth $58,000 after buying an additional 911 shares in the last quarter. Finally, Belpointe Asset Management LLC grew its position in shares of Natera by 127.2% during the 1st quarter. Belpointe Asset Management LLC now owns 1,586 shares of the medical research company's stock worth $88,000 after buying an additional 888 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,958 shares of the stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $68.16, for a total value of $133,457.28. Following the completion of the sale, the chief executive officer now directly owns 175,550 shares in the company, valued at $11,965,488. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, CFO Michael Burkes Brophy sold 1,378 shares of the firm's stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $92.62, for a total value of $127,630.36. Following the completion of the transaction, the chief financial officer now directly owns 70,646 shares in the company, valued at $6,543,232.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Steven Leonard Chapman sold 1,958 shares of the firm's stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $68.16, for a total value of $133,457.28. Following the completion of the transaction, the chief executive officer now owns 175,550 shares of the company's stock, valued at $11,965,488. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 453,293 shares of company stock worth $36,453,056. 9.42% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NTRA. The Goldman Sachs Group increased their price target on Natera from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Monday, April 15th. Stephens reissued an "overweight" rating and set a $78.00 price target on shares of Natera in a research report on Tuesday, January 30th. Piper Sandler increased their price target on Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 6th. Craig Hallum began coverage on Natera in a research report on Monday, April 8th. They set a "buy" rating and a $117.00 price target on the stock. Finally, Canaccord Genuity Group increased their price target on Natera from $87.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, February 29th. One research analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $86.40.

Natera Stock Down 2.3 %

Natera stock traded down $2.00 during midday trading on Friday, reaching $85.28. The company's stock had a trading volume of 2,526,074 shares, compared to its average volume of 1,116,438. The stock's 50-day simple moving average is $86.05 and its 200-day simple moving average is $66.17. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $98.82. The stock has a market capitalization of $10.30 billion, a P/E ratio of -22.50 and a beta of 1.37.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The company had revenue of $311.11 million during the quarter, compared to analysts' expectations of $300.38 million. On average, sell-side analysts expect that Natera, Inc. will post -2.35 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.